Provided by Tiger Fintech (Singapore) Pte. Ltd.

Theriva Biologics

0.5339
-0.0333-5.87%
Volume:572.68K
Turnover:304.93K
Market Cap:4.37M
PE:-0.03
High:0.5794
Open:0.5750
Low:0.5100
Close:0.5672
Loading ...

Theriva Biologics Q1 EPS $(1.55) Up From $(7.53) YoY

Benzinga
·
14 May

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

THOMSON REUTERS
·
14 May

Press Release: Theriva(TM) Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

Dow Jones
·
14 May

Theriva Biologics - Extending Its Cash Runway Into First Quarter of 2026

THOMSON REUTERS
·
14 May

Theriva Biologics Q1 2025: Reports Significant Changes in Revenue and Net Income, EPS Adjusts Accordingly

Reuters
·
14 May

Theriva Biologics Announces Closing of $7.5 Million Public Offering

THOMSON REUTERS
·
09 May

Press Release: Theriva Biologics Announces Closing of $7.5 Million Public Offering

Dow Jones
·
09 May

Theriva Biologics Cut to Hold From Buy by Maxim Group

Dow Jones
·
08 May

Theriva Biologics Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
08 May

BRIEF-Theriva Biologics Announces Pricing Of $7.5 Million Public Offering

Reuters
·
07 May

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

THOMSON REUTERS
·
07 May

BUZZ-Theriva Biologics soars after cancer drug meets main goal in mid-stage trial

Reuters
·
07 May

BRIEF-Theriva Biologics Announces Primary Endpoints For Efficacy And Safety Achieved In VIRAGE Phase 2B Clinical Trial Of VCN-01 With Gemcitabine/NAB-Paclitaxel In Newly-Diagnosed Metastatic Pancreatic Cancer Patients

Reuters
·
07 May

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in Virage Phase 2B Clinical Trial of Vcn-01 With Gemcitabine/Nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

THOMSON REUTERS
·
07 May

Theriva Biologics Inc - Vcn-01 Receives Orphan Drug and Fast Track Designation

THOMSON REUTERS
·
07 May

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

GlobeNewswire
·
10 Apr

Theriva™ Biologics Announces Positive Outcomes From the Second Meeting of the Independent Data Monitoring Committee for Virage, the Company’s Phase 2B Clinical Trial of Vcn-01 in Combination With Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (Pdac)

THOMSON REUTERS
·
31 Mar

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

GlobeNewswire
·
19 Mar

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire
·
19 Mar

Theriva Biologics Reports 2024 Financial Results and Progress

TIPRANKS
·
08 Mar